RT Journal Article
SR Electronic
T1 Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 212
OP 227
DO 10.20892/j.issn.2095-3941.2017.0054
VO 14
IS 3
A1 Zhang, Meng
A1 Liu, Ergang
A1 Cui, Yanna
A1 Huang, Yongzhuo
YR 2017
UL http://www.cancerbiomed.org/content/14/3/212.abstract
AB Multidrug resistance (MDR) is a major obstacle to successful cancer treatment and is crucial to cancer metastasis and relapse. Combination therapy is an effective strategy for overcoming MDR. However, the different pharmacokinetic (PK) profiles of combined drugs often undermine the combination effect in vivo, especially when greatly different physicochemical properties (e.g., those of macromolecules and small drugs) combine. To address this issue, nanotechnology-based codelivery techniques have been actively explored. They possess great advantages for tumor targeting, controlled drug release, and identical drug PK profiles. Thus, a powerful tool for combination therapy is provided, and the translation from in vitro to in vivo is facilitated. In this review, we present a summary of various combination strategies for overcoming MDR and the nanotechnology-based combination therapy.